Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies

被引：0
|
作者：
Wilky, Breelyn A.
Kumthekar, Priya
Wesolowski, Robert
Hwang, Jimmy J.
Raizer, Jeffrey J.
Gentry, Carleen
Ross, Ainsley
Drouin, Elise
Wilson, Nicholas
Shebanova, Olga
Goldberg, John M.
Buell, Jennifer
Stein, Robert Benjamin
Cuillerot, Jean-Marie
机构：
[1] Sylvester Comprehens Canc Ctr, Miami, FL USA
[2] Northwestern Mem Hosp, Chicago, IL 60611 USA
[3] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA
[4] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA
[5] Agenus Inc, Lexington, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3075
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3075
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors
    Gu, Shanzhi
    de Souza, Paul L.
    Shi, Yuankai
    Han, Weiqing
    Luo, SuXia
    Chen, Jing
    Day, Daphne
    Frentzas, Sophia
    Park, John J.
    Shao, Guoliang
    Wu, Shikai
    Fang, Meiyu
    Haydon, Andrew Mark
    Sun, Sanyuan
    Lei, Kaijian
    Ding, Luyin
    Zuo, Rui
    Gan, Xin
    Zhao, Yuansheng
    Chen, Xiaoxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: PART 1 RESULTS
    Friedman, Claire
    Carvajal, Richard
    Davar, Diwakar
    Castanon, Eduardo
    Ascierto, Paolo
    Calvo, Emiliano
    O'Hara, Mark
    Powell, Steven
    Shapira-Frommer, Ronnie
    Garralda, Elena
    Renouf, Daniel John
    Perets, Ruth
    Yunan, Mona
    Ravindran, Palanikumar
    Hammell, Amy
    O'Brien, Shaun
    Xu, Ke
    Wilson, Nicholas
    Jhatakia, Amy
    Mukhopadhyay, Anandaroop
    Gutierrez, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A620 - A621
  • [23] Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies.
    Waight, Jeremy
    Manrique, Mariana
    Gombos, Randi
    Costa, Matthew
    Iyer, Priyadarshini
    Vincent, Sylvia
    Ward, Rebecca
    Paltrinieri, Elena
    Chand, Dhan
    Wilson, Nicholas
    Buell, Jennifer
    Savitsky, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers
    Sakamuri, Divya
    Glitza, Isabella C.
    Cuellar, Sonia L. Betancourt
    Subbiah, Vivek
    Fu, Siqing
    Tsimberidou, Apostolia M.
    Wheler, Jennifer J.
    Hong, David S.
    Naing, Aung
    Falchook, Gerald S.
    Fanale, Michelle A.
    Cabanillas, Maria E.
    Janku, Filip
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (03) : 671 - 676
  • [25] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Phase I dose-finding study of a novel anti-CTLA-4 antibody ADG116 as monotherapy in patients with advanced solid tumors
    Richardson, G.
    Tolcher, A.
    Parnis, F.
    Park, J.
    Hamid, A.
    She, K.
    Liu, L.
    Zheng, S.
    Liu, G.
    Li, X.
    Li, B.
    Wang, X.
    Chen, M.
    Fischkoff, S.
    Gong, H.
    Luo, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1436 - S1437
  • [27] A phase Ia first-in-human study of JS']JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
    Zhang, J.
    Zhou, C.
    Jiang, J.
    Liu, H.
    Xiang, X.
    Wu, G.
    Zeng, R.
    Kuang, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S633 - S633
  • [28] MULTIPLE ASCENDING DOSE, OPEN-LABEL, PHASE 1/2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, TO INVESTIGATE THE SAFETY AND CLINICAL RESPONSE IN PATIENTS WITH CROHN'S DISEASE
    Tanida, Satoshi
    Matsuoka, Katsuyoshi
    Naganuma, Makoto
    Kitamura, Kazuya
    Matsui, Toshiyuki
    Arai, Makoto
    Fujiya, Mikihiro
    Horiki, Noriyuki
    Nebiki, Hiroko
    Kinjo, Fukunori
    Miyazaki, Takako
    Matsumoto, Takayuki
    Esaki, Motohiro
    Mitsuyama, Keiichi
    Saruta, Masayuki
    Ido, Akio
    Hojo, Seiichiro
    Takenaka, Osamu
    Oketani, Kiyoshi
    Imai, Toshio
    Tsubouchi, Hirohito
    Hibi, Toshifumi
    Kanai, Takanori
    GASTROENTEROLOGY, 2018, 154 (06) : S830 - S830
  • [29] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
12345